Whalesbook
Granules India has announced its audited financial results for the fiscal year ended March 31, 2026. The company posted consolidated revenue of ₹53,859.71 million and a consolidated profit after tax (PAT) of ₹5,950.21 million for FY26. Standalone revenue for the same period was ₹8,768.21 million, with a standalone PAT of ₹989.87 million.
The Board of Directors also recommended a final dividend of ₹1.75 per equity share for the financial year FY25-26, with a record date set for July 30, 2026. The 35th Annual General Meeting (AGM) is scheduled for August 6, 2026.
Granules India has been actively expanding its global footprint through strategic acquisitions. In April 2025, the company acquired Senn Chemicals AG in Switzerland to enhance its capabilities in peptides and immunotherapy APIs. Further strengthening its European presence, Granules India acquired a 100% stake in Granules Pharmaceuticals GmbH in Germany in November 2025. In the same month, it incorporated Granules Pharmaceuticals Canada, Inc., marking its formal entry into the Canadian market. The company also bolstered its capital structure by approving the issuance of 25,000,000 warrants convertible into equity shares, having received ₹3,656.25 million in consideration as of March 31, 2026.
A significant concern remains the USFDA warning letter issued in February 2025 for the Gagillapur facility. This has led to a voluntary pause in manufacturing and distribution from the unit, impacting revenue and increasing operational costs. The ongoing effects include higher expenses for consultancy, air freight, and production slowdowns, which continue to affect margins and revenue from this facility.
In terms of market context, pharmaceutical peers like Lupin and Sun Pharma have also navigated periods of USFDA scrutiny, often resulting in increased compliance costs and potential delays in product approvals. Granules India's recent acquisitions aim to diversify its revenue streams and reduce reliance on single-market or single-facility pressures, though regulatory challenges persist.
Looking ahead, investors will monitor the company's progress in addressing the USFDA's concerns at the Gagillapur facility and the lifting of any manufacturing restrictions. The integration and performance contributions of the recently acquired European entities and the Canadian subsidiary will also be key areas to track. Furthermore, performance in key regulated markets, particularly the US, will be observed against the backdrop of ongoing regulatory challenges. Updates from the AGM on August 6, 2026, are anticipated for management commentary.